Table 1.

Drug sensitivity of HEK-MRP5 and HEK-vector transfectants to various anticancer agents

DrugHEK-vector
HEK-MRP5
Resistance factor (n)
EC50 (μmol/L)
6-TG2.7 ± 0.1021.76 ± 1.39*8.0 (34)
5-FU12.85 ± 1.38134.37 ± 43.30*10.5 (8)
5′-Deoxy-5′-fluorouridine38.78 ± 9.7184.93 ± 26.162.2 (3)
Methotrexate0.014 ± 0.0030.07 ± 0.01*4.7 (3)
Pemetrexed0.048 ± 0.0040.36 ± 0.02*7.5 (15)
Cisplatin0.76 ± 0.181.78 ± 0.11*2.6 (3)
Oxaliplatin1.11 ± 0.163.40 ± 0.77*3.1 (4)
Doxorubicin0.03 ± 0.010.05 ± 0.01*2.0 (2)
Vincristine0.02 ± 0.0030.019 ± 0.0021.0 (2)
  • NOTE: Transfectants were grown for 3 days in the presence of the indicated drug; EC50 values were determined as described in Materials and Methods. Values are the mean ± SE of 2 to 34 independent experiments (n) determined in duplicate or triplicate. The resistance factor was calculated as the ratio of the EC50 value of the indicated HEK-MRP5 transfectant to the HEK-vector transfectant.

  • * Significantly different from HEK-vector cells by Student's paired t test (P ≤ 0.05).

  • Student's paired t test (P = 0.06).

  • Student's paired t test (P = 0.24).